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We have previously shown that functional components of the NF-nB signaling pathway are up-regulated and sequestered in the cytoplasm
of human papillomavirus 16 (HPV16)-transformed cell lines leading to a reduced activity of NF-nB. In this study, we examined the
expression of the NF-nB precursors p100 and p105 in keratinocytes transformed or not by HPV16. Western immunoblotting experiments
demonstrated high levels of p100 and p105 proteins not only in HPV16+ cervical carcinoma-derived keratinocytes but also in keratinocytes
stably transfected by HPV16 E6 or E7 oncogenes. Moreover, p100 and p105 proteins were predominantly cytoplasmic and nuclear in
keratinocytes expressing E7 and E6, respectively. A predominantly cytoplasmic localization of E7 protein was also detected in all
keratinocytes expressing E7. Our results suggest that HPV16 E6 and E7 proteins modulate the expression and the subcellular localization of
p100 and p105 NF-nB precursors.
D 2004 Elsevier Inc. All rights reserved.
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Cervical cancer, the second most frequent cause of death
by cancer among females worldwide, is associated with
human papillomavirus (HPV) infection and represents one
of the best examples of a human cancer preceded by a well-
characterized preneoplastic period (Parkin et al., 1988;
Richart, 1987). The HPV genome encodes for early proteins
including E1, E2, E4, E5, E6, and E7 and for late proteins
including L1 and L2. Among the early proteins, E6 and E7
are two oncoproteins that are always maintained and
expressed during all stages of malignant transformation
(for a review, see Mantovani and Banks, 2001; Munger and
Howley, 2002; Munger et al., 2001).
NF-nB is a pleiotropic transcription factor modulated by
a great variety of stimuli and viruses, which are able to
regulate the expression of many human and viral genes
(Pahl, 1999; Santoro et al., 2003). NF-nB complexes are0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: P.Delvenne@ulg.ac.be (P. Delvenne).formed of homo- or heterodimers derived from a family of
proteins that are all related to the viral v-Rel oncoprotein
(Baeuerle and Henkel, 1994; Bose, 1992; Richardson and
Gilmore, 1991; Siebenlist et al., 1994; Stephens et al., 1983;
Wilhelmsen et al., 1984). The human members of the so-
called Rel/NF-nB family are p50, p52, p65, RelB, and c-
Rel. p50 and p52 are derived from large cytoplasmic
precursors, named p105 and p100, respectively (Ghosh et
al., 1990; Kieran et al., 1990; Mercurio et al., 1992; Schmid
et al., 1991), while p65, RelB, and c-Rel harbor trans-
activating domains (Ballard et al., 1992; Grumont and
Gerondakis, 1989; Ryseck et al., 1992; Schmitz and
Baeuerle, 1991).
The activity of NF-nB complexes is regulated by a
second family of proteins named the InB family (Beg and
Baldwin, 1993; Haskill et al., 1991). The members InBa,
InBh, p105, and p100 inhibit the transcriptional activity of
NF-nB complexes by sequestering them in the cytoplasm
and blocking their binding to nB DNA sequences (Beg and
Baldwin, 1993; Henkel et al., 1992; Mercurio et al., 1993;
Naumann et al., 1993a, b; Thompson et al., 1995).05) 357–366
Fig. 1. Expression of E6 and E7 mRNAs and proteins in primary
keratinocytes (KN), HPV16-negative (HT3) and -positive (SiHa, CasKi)
cell lines, and in keratinocytes stably transfected by E6 and/or E7 (KE6,
KE7, and KE6/E7). (A) The expression of the full-length E6 and E7 mRNAs
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NF-nB or InB families are involved in cancer development.
The v-Rel-expressing viruses are highly oncogenic and
cause aggressive lymphomas in young birds (Moore and
Bose, 1988a, b) while mutated c-Rel has transforming
activity in vitro (Sylla and Temin, 1986). The genes coding
for c-Rel, p65, p50, p52, and Bcl-3 are located at sites of
recurrent chromosomal translocations and genomic rear-
rangements in human cancers (Gough et al., 2003; Liptay et
al., 1992; Lu et al., 1991; Mathew et al., 1993; Neri et al.,
1991; Ohno et al., 1990). NF-nB also regulates the
transcription of genes coding for extracellular proteases or
adhesion molecules and could therefore play a role in
angiogenesis or invasiveness, two mechanisms required for
tumor growth and development of metastasis (Chen et al.,
1995; Hansen et al., 1992; Pahl, 1999; Sato and Seiki,
1993). Another mechanism is the NF-nB-mediated regu-
lation of the expression of growth factors or oncoproteins
(GM-CSF, c-Myc, etc.), as well as of proteins derived from
tumor suppressor genes such as p53 (Duyao et al., 1990;
Pahl, 1999; Schreck and Baeuerle, 1990; Wu and Lozano,
1994). It is therefore possible that, in different cellular
environments, unregulated activation or inhibition of NF-nB
activity could be involved in tumor formation.
Concerning the interactions between NF-nB and HPV,
we, as other investigators, have shown that NF-nB (p50,
p65, and c-Rel) and InB (InBa) proteins are up-regulated
and sequestered in the cytoplasm of HPV+ keratinocytes
(Havard et al., 2002; Nees et al., 2001; Vancurova et al.,
2002), leading to a reduced constitutive activity of NF-nB
(Havard et al., 2002). As NF-nB has been shown to have a
repressive effect on the HPV16 LCR (Fontaine et al., 2000)
and to be associated with epithelial cell growth inhibition
(Qin et al., 1999; Seitz et al., 1998, 2000a, b; van
Hogerlinden et al., 1999), altered NF-nB activity in HPV+
keratinocytes may lead to an increased expression of the
HPV16 genome and to deregulated cell growth.
In order to better understand the mechanism of NF-nB
inhibition in HPV16-transformed keratinocytes, we studied
the expression of the p100 and p105 precursors, which are
potential inhibitors of NF-nB by sequestering, like InBa,
NF-nB dimers in the cytoplasm (Naumann et al., 1993a, b).
We describe, in the present report, a high expression of these
precursors in HPV16-transformed keratinocytes and dem-
onstrate that the expression and the subcellular localization
of p100 and p105 are influenced by the presence of the E6
and E7 viral oncoproteins.
were analyzed by RT-PCR. Twenty, 30, and 40 cycles of amplification were
carried out for E6 and E7 detection and the values obtained were
normalized in comparison with HPRT expression. The mean of the relative
values was next calculated to evaluate the relative expression of full-length
E6 and E7 mRNAs in the different keratinocytes tested. (B) One
representative PCR experiment (40 cycles) is illustrated. Specific primers
for HPV16-E6 recognize three E6 mRNAs, the full-length E6 mRNA (454
bp), and two spliced mRNAs (270 and 154 bp). Specific primers for
HPV16-E7 recognize only the full-length E7 mRNA. (C) Western blot
analysis of E6, wild-type p53, and E7 expression and subcellular
localization of E7 by using total, cytoplasmic, and nuclear extracts.Results
Expression of E6 and E7 mRNAs and proteins
We analyzed the expression of E6 and E7 mRNAs by
RT-PCR not only in HPV16-negative (HT3) and -positive
(SiHa, CasKi) keratinocyte-derived cell lines but also inprimary keratinocytes (KN) stably transfected or not by E6
(KE6), E7 (KE7), and E6/E7 (KE6/E7). Total RNA was
extracted and reverse transcribed. cDNA samples were
amplified by PCR by using specific primers for HPV16-E6
and HPV16-E7. Specific primers for HPV16-E6 amplified
the full-length E6 mRNA (454 bp) and two truncated
mRNAs derived from alternative splicing (E6*: 270 bp,
E6**: 154 bp). Specific primers for HPV16-E7 amplified
only the full-length E7 mRNA. The 20, 30, and 40 cycles of
amplification were carried out for E6 and E7 detection and
the values obtained were normalized in comparison with
HPRT expression. The mean of the relative values was next
calculated to evaluate the relative expression of full-length
E6 and E7 mRNAs in the different keratinocytes tested. As
shown in Fig. 1A, E6 and E7 mRNAs were undetectable in
primary keratinocytes and in the HT3 cell line, whereas
Fig. 2. p100 and p105 protein levels in primary keratinocytes (KN),
HPV16-negative (HT3) and -positive (SiHa, CasKi) cell lines, and in
keratinocytes stably transfected by E6 and/or E7 (KE6, KE7, and KE6/E7).
The levels of p100 and p105 proteins were determined by Western blot by
using total protein extracts as described under Materials and methods. Actin
was used as an internal control. This figure shows high amounts of p100
and p105 precursors in HPV16-positive cell lines (SiHa, CasKi) and in
keratinocytes stably transfected by E6 or E7.
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lines SiHa and CasKi (40 cycles). In addition, E6 mRNAs
were expressed in KE6 cells whereas E7 mRNA was
expressed in KE7 cells. Finally, E6 and E7 mRNAs were
simultaneously expressed in KE6/E7 cells (Fig. 1A). Con-
cerning the alternative splicing of E6 mRNAs, we observed
a strong expression of the full-length E6 mRNA in KE6 and
KE6/E7 cells, whereas the HPV
+ cell lines SiHa and CasKi
strongly expressed the truncated E6* mRNA (Fig. 1A).
Indeed, the relative expression of the full-length E6 mRNA
was KE6/E7 N KE6 N SiHa N CasKi (Fig. 1B). The relative
expression of the full-length E7 mRNAwas KE7 N KE6/E7 =
CasKi N SiHa (Fig. 1B). We also analyzed the expression
and the subcellular localization of HPV16-E6 and HPV16-
E7 oncoproteins by Western blot by using total, cytoplas-
mic, and nuclear protein extracts. As shown in Fig. 1C, the
expression of E7 was observed in SiHa and CasKi cell lines
but also in KE7 and KE6/E7 cells. The relative expression of
E7 protein was KE7 N KE6/E7 = CasKi N SiHa. We also
observed that E7 is predominantly cytoplasmic in all
keratinocytes tested since E7 was undetectable in the
nuclear fraction of all keratinocytes except for the KE7
cells, which expressed strongly the full-length E7 mRNA
(Fig. 1B). As shown in Fig. 1C, the expression of E6 was
detectable only in total protein extracts of KE6/E7 cells,
which expressed strongly the full-length E6 mRNA (Fig.
1B). The absence of E6 protein detection in SiHa and CasKi
HPV+ cell lines but also in KE6 cells could be explained by
a limited sensitivity of the anti-E6 antibody. Indeed, the E6
oncoprotein has been shown to be very difficult to detect
due to its high instability (Grossman and Laimins, 1989).
Due to this limit of detection and because p53 is targeted by
E6 for degradation (Scheffner et al., 1990), we monitored
the expression of wild-type p53 by Western Blot in all
keratinocytes tested to demonstrate indirectly the expression
of E6. As shown in Fig. 1C, the wild-type p53 protein was
detectable only in KE7 cells that do not express E6. In
primary keratinocytes, the expression of p53 was probably
under the limit of detection. Expression of wild-type p53
was not observed in HT3 cells because p53 is mutated in
these cells (Scheffner et al., 1991). In contrast, the detection
of p53 in KE7 cells was probably facilitated, in comparison
with primary keratinocytes, due to the stabilization of p53
by E7 (Eichten et al., 2002; Seavey et al., 1999). After
division in cytoplasmic and nuclear protein extracts, the
expression of E6 became undetectable by Western blot.
Therefore, we were unable to analyze its subcellular
localization.
High levels of p100 and p105 proteins in HPV + cell lines
and in keratinocytes stably transfected by E6 (KE6) and by
E7 (KE7)
To investigate whether p100 and p105 proteins were
expressed in cervical cancer cells, we screened various
HPV and HPV+ cell lines for the expression of theseproteins. Immunoblotting experiments detected high
amounts of p100 and p105 proteins in the two HPV16-
positive cell lines tested (SiHa, CasKi), while primary
cultures of human keratinocytes and the HT3 cell line
showed only small amounts of p100 and p105 (Fig. 2).
The p105 protein was detectable in primary cultures of
human keratinocytes after a prolonged exposition (data
not shown). Moreover, to better understand the specific
effects of E6 and E7, we also analyzed the expression of
p100 and p105 proteins in primary human keratinocytes
stably transfected by E6 (KE6), E7 (KE7), or the
combination E6/E7 (KE6/E7). Protein levels of p100 and
p105 were high in both KE6 and KE7 cells compared to
primary cultures of human keratinocytes (Fig. 2). How-
ever, the levels of p100 and p105 proteins were not or
only slightly increased in KE6/E7 cells relative to primary
human keratinocytes (Fig. 2). In order to further inves-
tigate if the function of p100 and p105 is regulated by
degradation or destabilization, the half-life of p100 and
p105 proteins was determined by Western blotting after
cycloheximide (CHX) treatment. Interestingly, p100 pro-
tein levels in KE6/E7 cells dramatically decreased 30 min
after CHX blocking, whereas 120 and 240 min were
necessary to observe protein level changes in KE7 and
KE6 cells, respectively. Treatment with CHX also resulted
in decreased p105 protein levels in KE6/E7 and KE6 cells
(within 3–4 h) whereas no change was observed for KE7
cells (within 6 h) (data not shown).
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cytoplasmic in HPV + cell lines
As a first step to investigate the function of p100 and
p105 proteins in cervical cancer cells, we studied their
subcellular localization. Nuclear and cytoplasmic extracts
from primary human keratinocytes, HPV16-negative (HT3)
and -positive (SiHa, CasKi) cell lines were run on an SDS-
PAGE gel and analyzed by immunoblot with specific
antibodies against p100 and p105. As shown in Fig. 3, the
higher amounts of p100 and p105 proteins, observed in
HPV16-positive cell lines, were detected predominantly in
the cytoplasm. In contrast, p100 and p105 were exclusively
detected in the nuclear fraction of primary human keratino-
cytes and the HT3 cell line. The detection of the p100 and
p105 precursors in the nuclear extracts was not a conse-
quence of a cytoplasmic contamination because we were
unable to detect, in the nuclear extracts, the InBa protein,
which is exclusively cytoplasmic in these cells (Havard et
al., 2002).
The p100 and p105 precursors are predominantly nuclear
in keratinocytes expressing only E6 (KE6) whereas they are
predominantly cytoplasmic in keratinocytes expressing E7
(KE7, KE6/E7)
To evaluate the potential influence of E6 and E7
expression on NF-nB activity, we also analyzed the
subcellular localization of p100 and p105 proteins in human
keratinocytes stably transfected or not by E6 and/or E7 (KN,
KE6, KE7, and KE6/E7). As shown in Fig. 3, the higher
amounts of p100 and p105 proteins, observed in KE6 and
KE7 cells, were predominantly cytoplasmic in keratinocytes
expressing E7 (KE7) but predominantly nuclear in keratino-
cytes expressing only E6 (KE6). In KE6 cells, p100 and p105
were detectable in the cytoplasm only after a prolonged
exposition (data not shown). In the KE6/E7 cells, the
unchanged amounts of p100 and p105 proteins were
predominantly detected in the cytoplasm. Again, the
detection of the p100 and p105 precursors in the nuclear
fraction was not a consequence of a cytoplasmic contam-
ination because we were unable to detect InBa in these
nuclear extracts (Fig. 3).Fig. 3. Subcellular localization of p100 and p105 precursors in primary
keratinocytes (KN), HPV16-negative (HT3) and -positive (SiHa, CasKi)
cell lines, and in keratinocytes transfected by E6 and/or E7 (KE6, KE7, and
KE6/E7). The cytoplasmic and nuclear protein levels of the p100 and p105
precursors were assessed by Western blot as described under Materials and
methods. Actin was used as an internal control. This figure shows a
differential subcellular localization of the p100 and p105 precursors in
HPV+ versus HPV cells. In HPV+ cells, p100 and p105 are predominantly
cytoplasmic whereas they are predominantly nuclear in HPV cells. This
figure also demonstrates a modulation of the subcellular localization of
p100 and p105 according to the expression of E6 and/or E7. In KE6 cells,
p100 and p105 are predominantly nuclear whereas they are predominantly
cytoplasmic in KE7 cells and distributed between the cytoplasm and the
nucleus in KE6/E7 cells. The detection of the p100 and p105 precursors in
the nuclear fraction was not a consequence of a cytoplasmic contamination
because InBa was not detected in these nuclear extracts.Discussion
NF-nB activity has been shown to be modulated by many
different virus such as HIV-1 (DeLuca et al., 1996; Roulston
et al., 1993), HTLV-1 (Hirai et al., 1992; Munoz et al.,
1994), EBV (Gutsch et al., 1994; Herrero et al., 1995), HBV
(Meyer et al., 1992; Su and Schneider, 1996), HCMV
(Kowalik et al., 1993; Yurochko et al., 1995), adenoviruses
(Schmitz et al., 1996), and more recently papillomaviruses
(Havard et al., 2002; Nees et al., 2001; Spitkovsky et al.,
2002; Vancurova et al., 2002). This study was performed to
L. Havard et al. / Virology 331 (2005) 357–366 361extend the knowledge about the effects of HPV on NF-nB
expression and activity.
We showed high levels of p100 and p105 NF-nB
precursors in cell lines derived from human cervical cancers
associated with HPV16 infection and in keratinocytes stably
transfected by E6 or E7 oncogenes. These results suggest
that both E6 and E7 oncoproteins are able to increase, by a
still unknown mechanism, the expression of NF-nB
precursors. However, in keratinocytes transfected by both
E6 and E7 oncogenes, the expression of p100 and p105 was
not or slightly increased compared to primary keratinocytes.
A potential explanation is that these precursors are targeted
for degradation when E6 and E7 oncoproteins are simulta-
neously expressed. The degradation of p100 and p105
precursors is regulated by the ubiquitin/proteasome pathway
(Fan and Maniatis, 1991; Heusch et al., 1999; Karin and
Ben-Neriah, 2000; Lee et al., 2001; Lin et al., 1998, 2000;
Orian et al., 1995, 1999; Palombella et al., 1994), which can
be stimulated by the E6/E7 combination towards specific
targets (Berezutskaya and Bagchi, 1997; Gross-Mesilaty et
al., 1998). In agreement with this hypothesis, the half-life of
p100 and p105 proteins was found to be shorter in KE6/E7
cells compared to KE6 (p100) and KE7 (p100 and p105).
Alternatively, E6 and E7, in combination, could stimulate
the activity of specific kinases that are known to phosphor-
ylate and accelerate the turnover of p100/p105 precursors
such as TPL-2, IKKa, IKKh, and NIK (Belich et al., 1999;
Heissmeyer et al., 1999; Orian et al., 2000; Salmeron et al.,
2001; Senftleben et al., 2001). For example, Nees et al.
(2001) have observed, by RT-PCR, higher levels of the
mRNA encoding for NIK in keratinocytes infected by
retroviruses expressing E6 and E7 of HPV16, suggesting
that NIK could be implicated in the degradation of p100 in
the presence of E6/E7. The high amounts of p100 and p105
precursors in SiHa and CasKi HPV16-positive cell lines in
spite of their simultaneous expression of E6 and E7
oncogenes could be explained by the differential pattern
of E6 splicing in these cells compared to KE6/E7 cells.
Indeed, the full-length E6 mRNAwas not expressed in SiHa
and CasKi cell lines whereas it was strongly expressed in
KE6/E7 cells. This observation suggests that the synergism
observed between E6 and E7 to reduce p100/p105 precursor
levels needs the full-length E6 oncoprotein. The degradation
of p100/p105 by the full-length E6/E7 combination could
create an alternative pathway controlling the NF-nB activity
in HPV+ keratinocytes by a continuous liberation of
particular NF-nB dimers such as p50/p50 and p52/p52
homodimers, which are preferentially bound by p105 and
p100, respectively (Chang et al., 1994; Liou et al., 1992). In
agreement with this hypothesis, Vancurova et al. (2002)
demonstrated an increased p50/p50 NF-nB activation in
HPV6- or 11-induced laryngeal papilloma tissues. These
data suggest that altered NF-nB pathways may not be
associated only with HPV16 proteins with oncogenic
activities. However, E6 and E7 are the only viral proteins
shown to be constantly expressed in cervical neoplasia andin cancer-derived cell lines, such as Caski and SiHa,
suggesting that the effect of E6 and E7 on the p100/p105
expression is most likely related to the full-length E6
oncoprotein.
With respect to the transforming activity of the E6 and
E7 oncoproteins, many investigators have reported the cell
location of these proteins, but the results are still con-
troversial. The E6 oncoprotein has been localized in the
cytoplasm and/or in the nucleus and the results seem to
depend on the cell type, the HPV type, and the experimental
strategy (Chen et al., 2001; Degenhardt and Silverstein,
2001; Kim et al., 1994; Le Roux and Moroianu, 2003; Liang
et al., 1993; Masson et al., 2003). Unfortunately, we have
been unable to analyze the subcellular localization of E6 due
to the reduced sensitivity of the anti-E6 antibody. Never-
theless, some recent studies demonstrated a preferential
nuclear localization of HPV16 E6 in cervical carcinoma
cells and characterized several pathways by which E6 enters
into the nucleus (Le Roux and Moroianu, 2003; Masson et
al., 2003). The HPV16 E7 oncoprotein has been also
localized in the cytoplasm and/or in the nucleus depending
on the cell type and the experimental strategy (Du et al.,
2003; Fujikawa et al., 1994; Kim et al., 1994; Tommasino et
al., 1990; Smith-McCune et al., 1999; Smotkin and
Wettstein, 1987). Although the E7 oncoprotein has been
shown to interact with both nuclear and cytoplasmic target
proteins (Zwerschke and Jansen-Durr, 2000), our data
suggest that the cytoplasmic localization of E7 predominates
not only in SiHa and CasKi HPV+ cell lines but also in KE7
and KE6/E7 cells. The demonstration that p100 and p105 are
predominantly cytoplasmic in the presence of E7 alone (KE7
cells), whereas they are predominantly nuclear in the
presence of E6 alone (KE6 cells), underlines a potential
modulation of the subcellular localization of p100 and p105
precursors by E6 and E7 expression. In agreement with this
hypothesis, we showed a colocalization of p100 and p105
precursors with E7 in the cytoplasm and a localization of
these precursors in the nucleus where E6 has been recently
detected (Le Roux and Moroianu, 2003; Masson et al.,
2003). When E6 and E7 proteins are simultaneously
expressed, the precursors are distributed between the
cytoplasm and the nucleus, as demonstrated in this study.
In addition, these observations suggest that the E6/E7 ratio
in the cell could determine the subcellular distribution of the
NF-nB precursors and raise the possibility of a direct
interaction between NF-nB precursors and E6/E7 proteins.
This hypothesis is conceivable since the E6 and E7
oncoproteins are able to interact directly with numerous
transcription factors, such as ADA3 (Kumar et al., 2002;
Zeng et al., 2002), CBP/p300 (Patel et al., 1999; Zimmer-
mann et al., 1999), and IRF-3 (Ronco et al., 1998) for E6
and TBP (Massimi et al., 1996; Phillips and Vousden,
1997), the TBP-associated factor 110 (TAF110) (Mazzarelli
et al., 1995), IRF-1 (Park et al., 2000; Perea et al., 2000),
and members of the AP1 family (Antinore et al., 1996) for
E7.
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exclusively detected in the nucleus of primary and HT3
keratinocytes. It was not a consequence of a cytoplasmic
contamination of nuclear extracts since we were unable to
detect InBa, an exclusively cytoplasmic protein in these
cells (Havard et al., 2002), in the nuclear extracts. The
presence of these precursors in the nucleus is surprising
since the nuclear localization sequence (NLS) of these
molecules has been shown to be masked by the folding of
the carboxy terminal end of the protein (Blank et al., 1991;
Henkel et al., 1992). However, Liao and Sun (2003) recently
demonstrated that the processing of p100 is regulated by its
nuclear shuttling. Possible explanations for the presence of
p100 and p105 in the nucleus of keratinocytes could be an
interaction between a keratinocyte-specific protein and the
carboxy-terminal end of these precursors preventing its
folding on the NLS or the nuclear shuttling of these
precursors for their processing.
Although a direct role of p100 and p105 proteins in
cervical carcinogenesis remains to be established, our results
suggest that these proteins may be involved in the trans-
formation of human cervical epithelial cells. NF-nB controls
the expression of many genes known to play a role in the
development of cancers. As some of these genes are
oncogenes (c-myc) or tumor suppressor genes (p53), both
an up-regulation or a down-regulation of intracellular NF-
nB activity could theoretically be responsible for cancer
development. Therefore, a more precise understanding of
the mechanisms by which HPV perturbs the expression and
the subcellular localization of NF-nB components but also,
consequently, the NF-nB activity could lead to the develop-
ment of new strategies to treat or prevent HPV-associated
cervical (pre)neoplastic lesions.Materials and methods
Cell culture and biological reagents
SiHa and CasKi cell lines are tumorigenic cervical
carcinoma-derived keratinocyte cell lines containing,
respectively, one copy and 300–600 copies of integrated
HPV16 DNA (Friedl et al., 1970; Pattillo et al., 1977). HT3
is a cervical carcinoma-derived cell line expressing a
mutated form of p53 (Scheffner et al., 1991) and classically
considered as negative for HPV, although some recent data
suggest that these cells may contain HPV30 (Naeger et al.,
1999). These cell lines were grown in medium consisting of
a 1/3 mixture of nutrient mixture F-12 (HAM)/Dulbecco’s
modified Eagle medium (DMEM) (Invitrogen, Merelbeke,
Belgium) and supplemented with 10% of bovine serum, 50
Ag/ml gentamicin, 2 mM glutamine, 1 mM sodium pyruvate
(Invitrogen), 1% nonessential amino acids, 0.4 Ag/ml
hydrocortisone (Sigma, Bornem, Belgium), and 2 ng/ml
EGF (Roche, Brussels, Belgium). Primary keratinocytes
(KN) were isolated from surgical specimens of uterinecervix and cultivated in vitro using a standard protocol
(Gilles et al., 1993). This study protocol was approved by
the Ethics committee of the University Hospital of Lie`ge.
Immortalized human foreskin keratinocytes stably trans-
fected with E6 and/or E7 were previously described
(Aguilar-Lemarroy et al., 2002) and kindly provided by F.
Rosl (Heidelberg, Germany).
Reverse transcriptase polymerase chain reaction (RT-PCR)
analysis
Total RNA was extracted using RNAwiz solution
(Ambion, Austin, USA) and 500 ng of total RNA was
reverse transcribed with Super-Script reverse transcriptase
(Invitrogen) using the procedure recommended by the
supplier. Samples were amplified using primers specific
for HPRT, E6, and E7. Nucleotide sequences for PCR
primers were as follows: HPRT sense, 5V-GTTGGATA-
TAAGCCAGACTTTGTTG-3 V: HPRT ant i sense ,
5VCAGATGTTTCCAAACTCAACTTGAA-3V: E6 sense,
5V-CAATGTTTCAGGACCCACAGGAGCG-3V: E6 anti-
sense, 5V-CAGCTGGGTTTCTCTACGTGTTCT-3V: E7
sense, 5V-GCAACCAGAGACAACTGATCTCTAC-3V: E7
antisense, 5V-GGTCTTCCAAAGTACGAATGTCTACG-3V.
The 25-Al PCR reaction included 1.5 Al of cDNA
mixture, 200 mM dNTP, 20 pM of each primer, and the
standard buffer supplemented with Taq polymerase
(GIBCO). The annealing temperature and the number of
cycles for each of the primer pairs were as follows: E6 55
8C/40, 30, 20 cycles; E7 55 8C/40, 30, 20 cycles; and HPRT
60 8C/35 cycles. Negative controls (H2O) were included in
each experiment. The PCR products were analyzed on an
ethidium bromide-stained agarose gel (1.8%) using the BIO-
PROFIL gel analyzer system (Vilber Lourmat, France) and
the results were normalized in comparison with HPRT.
Protein extraction
Total extracts were prepared by incubating keratinocytes
in lysis buffer (Roche) for 15 min at room temperature
followed by a centrifugation at 13000 rpm for 30 min to
eliminate insoluble components. The supernatants were
collected and represented the total protein extracts.
Nuclear and cytoplasmic extracts were prepared as
previously described (Dejardin et al., 1995). Briefly,
cytoplasmic buffer contained 20 mM HEPES, pH 7.9; 0.1
mM EDTA; 2 mM MgCl2; 10 mM KCl; 0.2% Nonidet P-40
and protease inhibitors (protease inhibitor kit, Roche). The
pelleted nuclei were resuspended in the nuclear buffer (20
mM HEPES, pH 7.9; 1.5 mM MgCl2; 0.2 mM EDTA; 0.63
mM NaCl; 25% glycerol and protease inhibitors), incubated
for 20 min at 4 8C, and centrifuged for 30 min at 14000 rpm.
Proteins were quantified with the Micro BCA Protein Assay
Reagent Kit (Pierce Chemical CO, Rockford, IL).
To determine the half-life of p100 and p105 proteins,
exponentially growing KE6, KE7, and KE6/E7 cells were
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(50 Ag/ml, Sigma) for periods of 0.5, 1, 2, 3, 4, 5, and 6 h.
Total cell extracts were then isolated using Roche lysis
buffer and subjected to immunoblot analysis for p100
(NFKB1) and p105 (NFKB2) expression.
Immunoblotting
Total, cytoplasmic, and nuclear extracts were separated
on a 10–18% SDS-PAGE gel. After transfer to a nylon
membrane (Amersham, Ghent, Belgium) and overnight
blocking at room temperature with Tris-buffered saline–
Tween (20 mM Tris pH 7.5, 500 mM NaCl, 0.2% Tween
20, and 5% dry milk), the membranes were incubated with
specific antibodies directed against p50–p105 (NFKB1),
p52–p100 (NFKB2) (Euromedex, Souffelweyersheim,
France), HPV16-E6 (Biognost-chemicon, Heule, Belgium),
and HPV16-E7 (Santa Cruz, CA, USA). The membranes
were then washed and incubated for 1 h with the
appropriate secondary peroxidase-conjugated antibody
(Amersham). The reaction was developed with the
enhanced chemiluminescence detection method (ECL and
ECL+ kits, Amersham). h-actin was used as an internal
control (Sigma).Acknowledgments
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